MNKD News | Roxom Stocks

Invest Private Security Newsroom

Market Overview

Indices and commodities.

Bitcoin treasury preferreds.

The artificial intelligence theme.

Bitcoin Treasuries

Companies holding bitcoin.

Sectors, global markets and rates.

Popular Portfolios

13F filings, smart money.

Borrow USDT or USDC against your BTC without giving it up.

Switch your bitcoin-backed loan and pay less interest.

Borrow, invest, keep the spread.

Stock Dividends

Dividends from tokenized equities.

Company

Our leadership team, mission, and investors.

Vision, purpose, and architecture behind Roxom.

Terms, privacy, and disclosures.

Resources

Guides, FAQs & support.

Trading logic, platform rules, and fundamentals.

Connect, authenticate, and build with our API.

Current platform health and incidents.

Loading chart

Pay with

1 BTC

=

- USD

Loading market data...

Loading chart

Pay with

MN

Mkt Cap

$979.1M

Volume

2.02M

Next Earnings

November 4th

Loading chart

MN

MNKDMannkind Corporation

MNKD

Pay with—

Available Balance0.00

MN

Mkt Cap

$1.03B

Volume

2.02M

Next Earnings

November 4th

Chart Financials Earnings News About Insider Filings

MannKind to Participate in the Chardan Healthcare ConferenceMannKind Corporation announced that CEO Michael Castagna will participate in a panel discussion on innovation in chronic respiratory diseases at the Chardan Healthcare Conference on October 20, 2026. The company will also conduct one-on-one investor meetings. MannKind is a biopharmaceutical company focused on cardiometabolic and orphan lung diseases, with treatments addressing diabetes, pulmonary hypertension, and fluid overload conditions.GlobeNewswire Inc. · Oct 14, 2026

MannKind Data at HFSA 2026 Highlights New Evidence Supporting Furoscix ReadyFlow™ for the Outpatient Management of Edema in Heart Failure (HF) and Chronic Kidney Disease (CKD)MannKind Corporation announced new clinical data for Furoscix ReadyFlow, an autoinjector delivering IV-equivalent diuretic therapy for heart failure and chronic kidney disease. Presented at the HFSA 2026 Annual Scientific Meeting, the data demonstrates comparable urine output to IV furosemide, consistent bioavailability across injection sites, and seamless transition capabilities from the previous On-body Infusor formulation. The product received FDA approval in July 2026 and is designed to enable earlier outpatient intervention for fluid overload management.GlobeNewswire Inc. · Oct 10, 2026

FDA Accepts United Therapeutics' NDA Filing for Ralinepag in PAHUnited Therapeutics announced FDA acceptance of its NDA for ralinepag, a once-daily oral prostacyclin receptor agonist for pulmonary arterial hypertension (PAH). The Phase III ADVANCE OUTCOMES study showed ralinepag reduced clinical worsening risk by 55% versus placebo and improved secondary endpoints. If approved in June 2027, it would be the first once-daily oral prostacyclin for PAH, complementing UTHR's existing PAH portfolio.Zacks Investment Research · Aug 28, 2026

Data at ADA 2026 Highlights Key Findings from Clinical and Real‑World Studies of MannKind’s Afrezza® (Inhaled Insulin) Across Pediatric Care, Pregnancy, and Use with Automated Insulin Delivery (AID) SystemsMannKind announced new clinical and real-world data for Afrezza (inhaled insulin) presented at the ADA 2026 Scientific Sessions, following the FDA approval for pediatric use (ages 6+) in May 2026. Key findings include greater treatment satisfaction in pediatric patients, comparable efficacy to rapid-acting analogs, potential use with automated insulin delivery systems, and earlier pharmacodynamic effect completion. The company also reported positive real-world evidence on lung cancer risk and FUROSCIX benefits in heart failure patients.GlobeNewswire Inc. · Jun 5, 2026

MannKind to Host Conference Call Today to Discuss Afrezza Pediatric ApprovalMannKind Corporation announced FDA approval of Afrezza®, the first and only inhaled mealtime insulin for children and adolescents aged 6 and older with diabetes. The company will host a conference call on May 29, 2026 at 4:30 p.m. Eastern with CEO Michael Castagna and other executives to discuss the approval.GlobeNewswire Inc. · May 29, 2026

MannKind to Present at Jefferies Global Healthcare ConferenceMannKind Corporation reported Q1 2026 total revenues of $90.2M, representing 15% growth compared to Q1 2025. The company announced CEO Michael Castagna will participate in a fireside chat at the 2026 Jefferies Global Healthcare Conference on June 3. MannKind also plans to showcase new data on inhaled insulin (Afrezza®) in pediatric care, pregnancy, and use with automated insulin delivery systems at ADA 2026.GlobeNewswire Inc. · May 27, 2026

The $59B Quiet Shift Reshaping How Patients Access CareThe point-of-care diagnostics market has reached $58.76 billion globally in 2026, growing at nearly 10% annually, with projections to reach $114.65 billion by 2035. Five companies are leading this structural shift toward decentralized, consumer-facing healthcare: VentriPoint Diagnostics is expanding globally with AI-powered cardiac imaging; Hims & Hers partnered with Novo Nordisk to offer affordable GLP-1 medications including Wegovy; MannKind is presenting clinical data on Afrezza inhaled insulin; and Ginkgo Bioworks launched Cloud Lab for remote access to autonomous lab infrastructure.Benzinga · May 12, 2026

A Key "Master" Protein That Declines by Half After Age 40. One Company Found a Way to Restore It.Avaí Bio announced it has initiated manufacturing of a Master Cell Bank of genetically modified cells that overexpress the α-Klotho protein, a key anti-aging protein that naturally declines by 50% after age 40. The milestone represents a transition from research to production infrastructure for their Klothonova anti-aging platform using Cell-in-a-Box® encapsulation technology. The cell therapy sector is rapidly expanding, with the global market projected to grow from $10.4 billion to over $45 billion by 2035.Benzinga · Mar 18, 2026

Why MannKind Stock Tumbled on ThursdayMannKind stock fell over 7% after reporting Q4 2025 earnings that showed a 46% revenue increase to $112 million, beating analyst estimates. However, the company's net income declined significantly to $1.5 million ($0.01 per share), missing the consensus estimate of $0.02 per share. The decline was driven by increased costs from integrating the Furoscix acquisition and higher R&D expenses. Despite the miss on profitability, the analyst argues the sell-off was unjustified given the company's strong pipeline.The Motley Fool · Feb 26, 2026

MannKind to Participate in the Oppenheimer 36th Annual Healthcare Life Sciences ConferenceMannKind Corporation announced that CEO Michael Castagna will present at the Oppenheimer 36th Annual Healthcare Life Sciences Conference on February 26, 2026. The company will also report its fourth quarter and full year 2025 financial results on the same date. Additionally, MannKind announced the first patient enrollment in the INHALE-1ST pediatric study evaluating Afrezza for youth with newly-diagnosed Type 1 Diabetes.GlobeNewswire Inc. · Feb 19, 2026

to start trading

MN

MNKDMannkind Corporation

MNKD

Pay with—

Available Balance0.00

Your PositionYou don't own any MNKD yet.

Related Tickers

Earnings